The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable anticipation within the sector. A shift away from Schedule I status, often considered as outdated and hindering progress, could unlock significant avenues for ventures. Reduced regulatory impediments, alongside greater access to banking and